Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Articles|December 8, 2021

Supplements and Featured Publications

Patients With Diabetes and Chronic Kidney Disease: ACE Inhibitor or ARB Treatment, Medical Costs for Disease Management, and the FINE-CKD Model to Evaluate Economic Value of Finerenone
Volume 27
Issue 20

eAppendix: ACE Inhibitor or ARB Treatment Among Patients With Diabetes and Chronic Kidney Disease

Author(s)Linda F. Fried, MD, MPH, Natalia Petruski-Ivleva, PhD, Kerstin Folkerts, MSc

Supplementary Appendix

Download PDF

Articles in this issue

over 4 years ago

Article

Patients With Diabetes and Chronic Kidney Disease: ACE Inhibitor or ARB Treatment, Medical Costs for Disease Management, and the FINE-CKD Model to Evaluate Economic Value of Finerenone - Participating Faculty

over 4 years ago

Article

ACE Inhibitor or ARB Treatment Among Patients With Diabetes and Chronic Kidney Disease

over 4 years ago

Article

Medical Costs for Managing Chronic Kidney Disease and Related Complications in Patients With Chronic Kidney Disease and Type 2 Diabetes

over 4 years ago

Article

FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

over 4 years ago

Article

eAppendix: FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Globe and stethoscope | Image Credit: Planetz - stock.adobe.com

Early-Onset CKD Mortality Declines Globally as Incidence Continues to Rise

ByBrooke McCormick

July 20th 2026

AJMC original research managerial

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

AJMC Letter to the Editor

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

AJMC original research policy

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

AJMC commentary

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

Trending on AJMC

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

Cardiology Prices Vary Widely by Insurer and State

Prior Cancer History Predicts Second Cancers in Polycythemia Vera, Essential Thrombocythemia

Hepatitis Prevention Programs Improve Liver Outcomes, but Gaps in Screening, Care Remain

Medicaid MFN Pricing Could Save $8.6 Billion